For research use only. Not for therapeutic Use.
(E,E)-RGFP966 is a selective and CNS permeable HDAC3 inhibitor that can be used for the research of Huntington’s disease[1].
| Catalog Number | R061210 |
| CAS Number | 1396841-57-8 |
| Synonyms | (E)-N-(2-amino-4-fluorophenyl)-3-[1-[(E)-3-phenylprop-2-enyl]pyrazol-4-yl]prop-2-enamide |
| Molecular Formula | C21H19FN4O |
| Purity | ≥95% |
| InChI | InChI=1S/C21H19FN4O/c22-18-9-10-20(19(23)13-18)25-21(27)11-8-17-14-24-26(15-17)12-4-7-16-5-2-1-3-6-16/h1-11,13-15H,12,23H2,(H,25,27)/b7-4+,11-8+ |
| InChIKey | BLVQHYHDYFTPDV-VCABWLAWSA-N |
| SMILES | C1=CC=C(C=C1)C=CCN2C=C(C=N2)C=CC(=O)NC3=C(C=C(C=C3)F)N |
| Reference | [1]. Jia H, et al. The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington’s Disease Mice. PLoS One. 2016 Mar 31;11(3):e0152498. |
